Zai Lab (09688) rose more than 3% again, and as of press time, it increased by 3.50%, reporting 14.78 Hong Kong dollars, with a turnover of 9.3122 million Hong Kong dollars.
According to the Zhongtong Finance APP, Zai Lab (09688) rose more than 3% again, and as of press time, it increased by 3.50%, reporting 14.78 Hong Kong dollars, with a turnover of 9.3122 million Hong Kong dollars.
Recently, Zai Lab and argenx announced that the subcutaneous injection of efgartigimod was approved by the National Medical Products Administration to be used in conjunction with conventional treatment drugs for the treatment of adult generalized myasthenia gravis (gMG) patients with acetylcholine receptor-positive. This is also the first subcutaneous injection approved for the treatment of generalized myasthenia gravis in China.
In a previous research report, Puissance International maintained a “buy” rating on Zai Lab, and increased the revenue forecast for 2024E and 2025E by 7.5% and 3.1%, respectively. This is mainly due to the increase in revenue from efgartigimod and upcoming new drugs that are expected to be approved.